You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropofol
Accession NumberDB00818  (APRD01201, EXPT02558, DB05893)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionPropofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
Structure
Thumb
Synonyms
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Propofol
Propofol
Propofol
Propofolum
Rapinovet
External Identifiers
  • ICI 35868
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Propofolemulsion10 mgintravenousActavis Pharma Company2015-11-20Not applicableCanada
Diprivaninjection, emulsion10 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Diprivaninjection, emulsion10 mg/mLintravenousFresenius Kabi USA, LLC2009-11-13Not applicableUs
Diprivan Eml IV 1%emulsion1 %intravenousAstrazeneca Canada Inc1993-12-31Not applicableCanada
PMS-propofolemulsion10 mgintravenousPharmascience Inc2002-03-01Not applicableCanada
Propofolinjection, emulsion10 mg/mLintravenousAPP Pharmaceuticals, LLC2009-10-07Not applicableUs
Propofol Injectionemulsion1 %intravenousFresenius Kabi Canada Ltd2015-06-01Not applicableCanada
Propofol Injectionemulsion10 mgintravenousHospira Healthcare Corporation1998-02-05Not applicableCanada
Propofol Injectionemulsion10 mgintravenousNovopharm Limited2000-07-052013-04-01Canada
Propofol Injectionemulsion10 mgintravenousHospira Healthcare Corporation2004-04-022011-11-28Canada
Propofol-II Injectionemulsion10 mgintravenousHospira Healthcare Corporation2013-06-11Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Propofolinjection, emulsion10 mg/mLintravenousHospira, Inc.2006-03-17Not applicableUs
Propofolinjection, emulsion10 mg/mLintravenousTeva Parenteral Medicines, Inc.2007-06-21Not applicableUs
Propofolinjection, emulsion10 mg/mLintravenousActavis Pharma, Inc.2015-10-30Not applicableUs
Propofolinjection, emulsion10 mg/mLintravenousSagent Pharmaceuticals2014-07-01Not applicableUs
Propofolinjection, emulsion10 mg/mLintravenousTeva Parenteral Medicines, Inc.2007-06-21Not applicableUs
Propofolinjection, emulsion10 mg/mLintravenousGeneral Injectables and Vaccines, Inc2014-08-21Not applicableUs
Propofolinjection, emulsion10 mg/mLintravenousTeva Parenteral Medicines, Inc.2007-06-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnepolHa Na Pharm
AnesproBehrens
AnesvanChi Sheng
CritifolAbbott
DisoprivanAstraZeneca
DormofolActavis
FresofolBoryung
GobbifolGobbi
HipnolamAC Farma
HyproCelon
IV-ProClaris Lifesciences
LipuroB. Braun Medical
Oleo-LaxFada
PlofedWarsaw Pharmaceutical Works
ProfolBiogalenic
ProfolenBlausiegel
PropofabbHospira
PropofilAlvia
PropogenGenepharm
PropolipidFresenius
PropovanBharat Serums
PropovenFresenius
ProviveAFT
RecofolBayer
SafolNovell
TrivamHana Pharm
TroypofolTroikaa
UnifolClaris Lifesciences
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYI7VU623SF
CAS number2078-54-8
WeightAverage: 178.2707
Monoisotopic: 178.135765198
Chemical FormulaC12H18O
InChI KeyInChIKey=OLBCVFGFOZPWHH-UHFFFAOYSA-N
InChI
InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
IUPAC Name
2,6-bis(propan-2-yl)phenol
SMILES
CC(C)C1=CC=CC(C(C)C)=C1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassCumenes
Direct ParentCumenes
Alternative Parents
Substituents
  • Phenylpropane
  • Cumene
  • Phenol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.
PharmacodynamicsPropofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).
Mechanism of actionThe action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.
Related Articles
AbsorptionRapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.
Volume of distribution
  • 60 L/kg [healthy adults]
Protein binding95 to 99%, primarily to serum albumin and hemoglobin
Metabolism

Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.

SubstrateEnzymesProduct
Propofol
4-HydroxypropofolDetails
Propofol
Propofol glucuronideDetails
Propofol glucuronide
Not Available
1-Quinol glucuronideDetails
4-Hydroxypropofol
1-Quinol glucuronideDetails
4-Hydroxypropofol
Not Available
4-Quinol sulfateDetails
Route of eliminationIt is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.
Half lifeInitial distribution phase t1/2α=1.8-9.5 minutes. Second redistirubtion phase t1/2β=21-70 minutes. Terminal elimination phase t1/2γ=1.5-31 hours.
Clearance
  • 23 – 50 mL/kg/min
  • 1.6 – 3.4 L/min [70 Kg adults]
ToxicityOverdosage may increase pharmacologic and adverse effects or cause death.

IV LD50=53 mg/kg (mice), 42 mg/kg (rats). Oral LD50 (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9381
Caco-2 permeable+0.9153
P-glycoprotein substrateNon-substrate0.722
P-glycoprotein inhibitor INon-inhibitor0.9343
P-glycoprotein inhibitor IINon-inhibitor0.9883
Renal organic cation transporterNon-inhibitor0.9036
CYP450 2C9 substrateNon-substrate0.7352
CYP450 2D6 substrateSubstrate0.7838
CYP450 3A4 substrateNon-substrate0.5667
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9368
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9196
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7429
Ames testNon AMES toxic0.9282
CarcinogenicityNon-carcinogens0.7195
BiodegradationNot ready biodegradable0.7808
Rat acute toxicity2.2996 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8987
hERG inhibition (predictor II)Non-inhibitor0.9087
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Emulsionintravenous1 %
Injection, emulsionintravenous10 mg/mL
Emulsionintravenous10 mg
Prices
Unit descriptionCostUnit
Diprivan 10 mg/ml vial0.93USD ml
Propoven 1000 mg/100 ml vial0.19USD ml
Propoven 200 mg/20 ml ampul0.19USD ml
Propoven 500 mg/50 ml vial0.19USD ml
Propofol 10 mg/ml vial0.13USD ml
Propofol 1% emulsion vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2212794 No2000-09-122015-03-17Canada
US5714520 Yes1995-09-222015-09-22Us
US5731355 Yes1995-09-222015-09-22Us
US5731356 Yes1995-09-222015-09-22Us
US5908869 Yes1995-09-222015-09-22Us
US8476010 Yes2005-06-012025-06-01Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point18 °CPhysProp
boiling point256 °CPhysProp
water solubility124 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
pKa11.1 (at 20 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.158 mg/mLALOGPS
logP3.81ALOGPS
logP4.16ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)10.98ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity56.42 m3·mol-1ChemAxon
Polarizability21.61 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03di-2900000000-52d81dde2dccf378a450View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

John R. Carpenter, “Propofol-based anesthetic and method of making same.” U.S. Patent US6150423, issued May, 1977.

US6150423
General References
  1. Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [PubMed:12904852 ]
  2. Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [PubMed:18326136 ]
  3. Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Jun;25(6):460-7. doi: 10.1017/S026502150800375X. Epub 2008 Feb 26. [PubMed:18298873 ]
External Links
ATC CodesN01AX10
AHFS Codes
  • 28:04.92
PDB EntriesNot Available
FDA labelDownload (168 KB)
MSDSDownload (71.9 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Propofol is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Propofol can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Propofol is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Propofol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Propofol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Propofol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Propofol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Propofol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propofol.
AmiodaronePropofol may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Propofol can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Propofol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Propofol is combined with Amperozide.
AnagrelidePropofol may increase the QTc-prolonging activities of Anagrelide.
AprepitantThe serum concentration of Propofol can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Propofol.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propofol.
ArmodafinilThe metabolism of Propofol can be decreased when combined with Armodafinil.
Arsenic trioxidePropofol may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherPropofol may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Propofol can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Propofol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Propofol is combined with Asenapine.
AtazanavirThe metabolism of Propofol can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Propofol can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Azaperone.
AzelastinePropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Propofol.
AzithromycinPropofol may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Propofol can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Propofol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Barbital.
BedaquilinePropofol may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Propofol is combined with Benzyl alcohol.
BetaxololThe metabolism of Propofol can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Propofol can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Propofol can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Propofol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Propofol can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Propofol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.
BrimonidineThe risk or severity of adverse effects can be increased when Propofol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Propofol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Propofol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.
BuprenorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Buprenorphine.
BupropionThe metabolism of Propofol can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propofol.
ButacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Propofol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Propofol is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propofol.
CaffeineThe metabolism of Propofol can be decreased when combined with Caffeine.
CapecitabineThe metabolism of Propofol can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Propofol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Propofol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Propofol is combined with Carisoprodol.
CelecoxibThe metabolism of Propofol can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Propofol can be increased when it is combined with Ceritinib.
CeritinibPropofol may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Propofol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Propofol is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Propofol can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propofol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Chloroprocaine.
ChloroquinePropofol may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Propofol can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorphenamine.
ChlorpromazinePropofol may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Propofol can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Propofol can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Propofol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Propofol can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propofol.
CiprofloxacinPropofol may increase the QTc-prolonging activities of Ciprofloxacin.
CisapridePropofol may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Propofol is combined with Citalopram.
CitalopramThe metabolism of Propofol can be decreased when combined with Citalopram.
ClarithromycinPropofol may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Propofol can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Propofol can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Propofol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Propofol is combined with Clidinium.
ClobazamThe metabolism of Propofol can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Propofol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Propofol is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Propofol is combined with Clomipramine.
ClomipramineThe metabolism of Propofol can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Propofol is combined with Clonidine.
ClopidogrelThe metabolism of Propofol can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propofol.
ClotrimazoleThe metabolism of Propofol can be decreased when combined with Clotrimazole.
ClozapinePropofol may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Propofol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Propofol can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Propofol.
ConivaptanThe serum concentration of Propofol can be increased when it is combined with Conivaptan.
CrizotinibPropofol may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Propofol can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Propofol can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Propofol can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Propofol can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propofol.
DapoxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Dapoxetine.
DarifenacinThe metabolism of Propofol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Propofol can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Propofol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Propofol can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Propofol can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Propofol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Desflurane.
DesipramineThe metabolism of Propofol can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Propofol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Propofol is combined with Detomidine.
DexamethasoneThe serum concentration of Propofol can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propofol.
DextromoramideThe risk or severity of adverse effects can be increased when Propofol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propofol.
DezocineThe risk or severity of adverse effects can be increased when Propofol is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Propofol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Propofol can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydromorphine.
DiltiazemThe metabolism of Propofol can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Propofol is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Propofol can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenoxylate.
DisopyramidePropofol may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Propofol can be decreased when combined with Disulfiram.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Propofol.
DolasetronPropofol may increase the QTc-prolonging activities of Dolasetron.
DomperidonePropofol may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Propofol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Propofol is combined with Doxepin.
DoxorubicinThe metabolism of Propofol can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Propofol can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol.
DoxylamineThe risk or severity of adverse effects can be increased when Propofol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Propofol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Propofol.
DronedaroneThe metabolism of Propofol can be decreased when combined with Dronedarone.
DronedaronePropofol may increase the QTc-prolonging activities of Dronedarone.
DroperidolPropofol may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Propofol.
DrotebanolThe risk or severity of adverse effects can be increased when Propofol is combined with Drotebanol.
DuloxetineThe metabolism of Propofol can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.
EcgonineThe risk or severity of adverse effects can be increased when Propofol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Propofol is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Propofol can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Propofol is combined with Efavirenz.
EliglustatPropofol may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Propofol can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Propofol.
EntacaponeThe risk or severity of adverse effects can be increased when Propofol is combined with Entacapone.
EnzalutamideThe serum concentration of Propofol can be decreased when it is combined with Enzalutamide.
ErythromycinPropofol may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Propofol can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Propofol is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Propofol can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Propofol can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propofol.
EthanolPropofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Propofol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.
EthosuximideThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Propofol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Propofol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Propofol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Propofol.
EtoperidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Etorphine.
EtravirineThe serum concentration of Propofol can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Propofol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Propofol is combined with Felbamate.
FelodipineThe metabolism of Propofol can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Propofol is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Propofol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propofol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.
FexofenadineThe risk or severity of adverse effects can be increased when Propofol is combined with Fexofenadine.
FlecainidePropofol may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Propofol.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Propofol.
FloxuridineThe metabolism of Propofol can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Propofol can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Propofol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Flunitrazepam.
FluorouracilThe metabolism of Propofol can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Fluoxetine.
FluoxetineThe metabolism of Propofol can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Propofol is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol.
FluspirileneThe risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Propofol is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Propofol can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Propofol is combined with Fluvoxamine.
FluvoxamineThe metabolism of Propofol can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Propofol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Propofol can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Propofol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fospropofol.
Fusidic AcidThe serum concentration of Propofol can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Propofol is combined with gabapentin enacarbil.
Gadobenic acidPropofol may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Propofol is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Propofol can be decreased when combined with Gemfibrozil.
GemifloxacinPropofol may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Propofol is combined with Glutethimide.
GoserelinPropofol may increase the QTc-prolonging activities of Goserelin.
GranisetronPropofol may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Propofol.
HaloperidolPropofol may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Propofol can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Propofol is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Propofol is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Hexobarbital.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Propofol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Propofol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Propofol.
HydroxyzineThe risk or severity of adverse effects can be increased when Propofol is combined with Hydroxyzine.
IbutilidePropofol may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Propofol can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Iloperidone.
ImatinibThe metabolism of Propofol can be decreased when combined with Imatinib.
ImipramineThe metabolism of Propofol can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Propofol is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Propofol is combined with Indalpine.
IndinavirThe metabolism of Propofol can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Propofol can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Propofol.
IsavuconazoniumThe metabolism of Propofol can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Propofol.
IsoniazidThe metabolism of Propofol can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Propofol can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Propofol can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Propofol can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Ketobemidone.
KetoconazoleThe metabolism of Propofol can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Propofol is combined with Lamotrigine.
LapatinibThe metabolism of Propofol can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Propofol can be decreased when combined with Leflunomide.
LenvatinibPropofol may increase the QTc-prolonging activities of Lenvatinib.
LeuprolidePropofol may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Propofol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Propofol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Propofol is combined with Levodopa.
LevofloxacinPropofol may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Propofol is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Propofol is combined with Levorphanol.
LidocaineThe metabolism of Propofol can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Propofol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Lofentanil.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Propofol.
LopinavirThe metabolism of Propofol can be decreased when combined with Lopinavir.
LopinavirPropofol may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Propofol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Propofol.
LorcaserinThe metabolism of Propofol can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Propofol can be decreased when combined with Losartan.
LovastatinThe metabolism of Propofol can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.
Lu AA21004The risk or severity of adverse effects can be increased when Propofol is combined with Lu AA21004.
LuliconazoleThe serum concentration of Propofol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Propofol can be decreased when it is combined with Lumacaftor.
LumefantrinePropofol may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Propofol can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propofol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Propofol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Propofol is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Propofol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Propofol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Propofol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.
MesoridazineThe risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.
MethadonePropofol may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Propofol can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Propofol is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Propofol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Propofol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Propofol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Propofol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Methylphenobarbital.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propofol.
MetoprololThe metabolism of Propofol can be decreased when combined with Metoprolol.
MetyrosinePropofol may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Propofol can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Propofol can be increased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Midazolam.
MifepristoneThe metabolism of Propofol can be decreased when combined with Mifepristone.
MifepristonePropofol may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Propofol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.
MirabegronThe metabolism of Propofol can be decreased when combined with Mirabegron.
MirtazapinePropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propofol.
MitotaneThe serum concentration of Propofol can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Propofol can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Propofol can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Propofol is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Propofol.
MoxifloxacinPropofol may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.
NabiloneThe risk or severity of adverse effects can be increased when Propofol is combined with Nabilone.
NafcillinThe serum concentration of Propofol can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Propofol is combined with Nalbuphine.
NefazodoneThe metabolism of Propofol can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Propofol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Propofol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Propofol can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Propofol can be decreased when combined with Nicardipine.
NicotineThe metabolism of Propofol can be decreased when combined with Nicotine.
NilotinibThe metabolism of Propofol can be decreased when combined with Nilotinib.
NilotinibPropofol may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Propofol.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Propofol.
NitrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Propofol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Nortriptyline.
OfloxacinPropofol may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Propofol is combined with Olanzapine.
OlaparibThe metabolism of Propofol can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Propofol is combined with Olopatadine.
OmeprazoleThe metabolism of Propofol can be decreased when combined with Omeprazole.
OndansetronPropofol may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Propofol.
OpiumThe risk or severity of adverse effects can be increased when Propofol is combined with Opium.
OrphenadrinePropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Propofol.
OsanetantThe risk or severity of adverse effects can be increased when Propofol is combined with Osanetant.
OsimertinibThe serum concentration of Propofol can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propofol.
OxymorphoneThe risk or severity of adverse effects can be increased when Propofol is combined with Oxymorphone.
PalbociclibThe serum concentration of Propofol can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Paliperidone.
PanobinostatPropofol may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Propofol can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Propofol can be decreased when combined with Pantoprazole.
ParaldehydePropofol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Propofol.
ParoxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Paroxetine.
ParoxetineThe metabolism of Propofol can be decreased when combined with Paroxetine.
PazopanibPropofol may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePropofol may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Propofol.
PerampanelThe risk or severity of adverse effects can be increased when Propofol is combined with Perampanel.
PerflutrenPropofol may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Propofol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propofol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Propofol is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Propofol is combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Propofol.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Propofol.
PioglitazoneThe metabolism of Propofol can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Propofol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Propofol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.
PosaconazoleThe metabolism of Propofol can be decreased when combined with Posaconazole.
PramipexolePropofol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Propofol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Propofol.
PrimaquinePropofol may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Primidone.
ProcainamidePropofol may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Propofol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.
PromazinePropofol may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Propofol can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Propofol is combined with Promethazine.
PropafenonePropofol may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Propofol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Propofol is combined with PSD502.
PyrimethamineThe metabolism of Propofol can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Propofol can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Propofol is combined with Quetiapine.
QuinidinePropofol may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Propofol can be decreased when combined with Quinidine.
QuininePropofol may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Propofol can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Propofol can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon.
RanolazineThe metabolism of Propofol can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.
RifabutinThe metabolism of Propofol can be increased when combined with Rifabutin.
RifampicinRifampicin may increase the hypotensive activities of Propofol.
RifapentineThe metabolism of Propofol can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Propofol.
RitonavirThe metabolism of Propofol can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Propofol can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Propofol is combined with Romifidine.
RopinirolePropofol may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Propofol can be decreased when combined with Ropinirole.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Propofol.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Propofol.
RosiglitazoneThe metabolism of Propofol can be decreased when combined with Rosiglitazone.
RotigotinePropofol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Propofol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Propofol is combined with S-Ethylisothiourea.
SaquinavirPropofol may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Propofol can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Propofol.
SertindoleThe risk or severity of adverse effects can be increased when Propofol is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Propofol is combined with Sertraline.
SertralineThe metabolism of Propofol can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.
SildenafilThe metabolism of Propofol can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Propofol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Propofol can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Propofol is combined with Sodium oxybate.
SorafenibThe metabolism of Propofol can be decreased when combined with Sorafenib.
SotalolPropofol may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Propofol can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Propofol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.
SulfadiazineThe metabolism of Propofol can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Propofol can be decreased when combined with Sulfamethoxazole.
SulfisoxazolePropofol may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Propofol can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propofol.
SuvorexantThe risk or severity of adverse effects can be increased when Propofol is combined with Suvorexant.
TamoxifenThe metabolism of Propofol can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Propofol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Propofol is combined with Tasimelteon.
TelaprevirThe metabolism of Propofol can be decreased when combined with Telaprevir.
TelavancinPropofol may increase the QTc-prolonging activities of Telavancin.
TelithromycinPropofol may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Propofol can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Propofol.
TenofovirThe metabolism of Propofol can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Propofol can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Propofol can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Propofol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrodotoxin.
ThalidomidePropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Propofol.
TheophyllineThe metabolism of Propofol can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Propofol is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Propofol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propofol.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Propofol.
ThiotepaThe metabolism of Propofol can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Propofol is combined with Tiagabine.
TicagrelorThe metabolism of Propofol can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Propofol can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Propofol is combined with Tiletamine.
TipranavirThe metabolism of Propofol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Propofol is combined with Tizanidine.
TocilizumabThe serum concentration of Propofol can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Propofol can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Propofol is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Propofol is combined with Topiramate.
ToremifenePropofol may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propofol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Propofol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Propofol can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Propofol is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Propofol is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propofol.
TrimethoprimThe metabolism of Propofol can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Propofol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Propofol is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Propofol.
ValsartanThe metabolism of Propofol can be decreased when combined with Valsartan.
VandetanibPropofol may increase the QTc-prolonging activities of Vandetanib.
VemurafenibThe serum concentration of Propofol can be increased when it is combined with Vemurafenib.
VemurafenibPropofol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Propofol can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Propofol can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Propofol is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Propofol is combined with Vilazodone.
VoriconazoleThe metabolism of Propofol can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Propofol is combined with Xylazine.
ZafirlukastThe metabolism of Propofol can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Propofol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Propofol is combined with Zimelidine.
ZiprasidoneThe metabolism of Propofol can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Propofol.
ZonisamideThe risk or severity of adverse effects can be increased when Propofol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Propofol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Propofol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Propofol is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeleta...
Gene Name:
SCN4A
Uniprot ID:
P35499
Molecular Weight:
208059.175 Da
References
  1. Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. doi: 10.1038/bjp.2008.255. Epub 2008 Jun 23. [PubMed:18574460 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN2A
Uniprot ID:
Q99250
Molecular Weight:
227972.64 Da
References
  1. Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. doi: 10.1038/bjp.2008.255. Epub 2008 Jun 23. [PubMed:18574460 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):131-6. doi: 10.1111/j.1742-7843.2008.00247.x. [PubMed:18816295 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Mano Y, Usui T, Kamimura H: Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4. [PubMed:17697043 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Fatty acid amide hydrolase activity
Specific Function:
Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.
Gene Name:
FAAH
Uniprot ID:
O00519
Molecular Weight:
63065.28 Da
References
  1. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. doi: 10.1093/nar/gkp1014. Epub 2009 Nov 20. [PubMed:19933260 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Molecular Weight:
60750.215 Da
References
  1. Gu J, Lu K, Xia P, Tang M, Dai Q, Ma D, Tao G: Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26. doi: 10.1159/000236523. Epub 2009 Sep 10. [PubMed:19752585 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bright DP, Adham SD, Lemaire LC, Benavides R, Gruss M, Taylor GW, Smith EH, Franks NP: Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel. J Biol Chem. 2007 Apr 20;282(16):12038-47. Epub 2007 Feb 20. [PubMed:17311911 ]
  2. Liu R, Eckenhoff RG: Weak polar interactions confer albumin binding site selectivity for haloether anesthetics. Anesthesiology. 2005 Apr;102(4):799-805. [PubMed:15791110 ]
  3. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
  4. Schywalsky M, Ihmsen H, Knoll R, Schwilden H: Binding of propofol to human serum albumin. Arzneimittelforschung. 2005;55(6):303-6. [PubMed:16032968 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40